Meridian Bioscience (VIVO) stock price, revenue, and financials

Meridian Bioscience market cap is $491.9 m, and annual revenue was $213.57 m in FY 2018

$491.9 M

VIVO Mkt cap, 10-Jun-2019

$48.4 M

Meridian Bioscience Revenue Q3, 2019
Meridian Bioscience Gross profit (Q3, 2019)28.3 M
Meridian Bioscience Gross profit margin (Q3, 2019), %58.3%
Meridian Bioscience Net income (Q3, 2019)5.1 M
Meridian Bioscience EBIT (Q3, 2019)6.5 M
Meridian Bioscience Cash, 30-Jun-201955.2 M
Meridian Bioscience EV512.6 M

Meridian Bioscience Revenue

Meridian Bioscience revenue was $213.57 m in FY, 2018

Embed Graph

Meridian Bioscience Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

188.7m188.8m194.8m196.1m200.8m213.6m

Revenue growth, %

0%3%1%

Cost of goods sold

67.6m71.6m72.9m68.3m75.9m83.1m

Gross profit

121.0m117.2m121.9m127.8m124.8m130.5m

Gross profit Margin, %

64%62%63%65%62%61%

Sales and marketing expense

22.4m24.9m25.6m29.9m32.1m34.5m

R&D expense

10.8m12.6m12.6m13.8m15.7m16.9m

General and administrative expense

30.5m27.4m27.6m30.6m32.3m34.5m

Operating expense total

63.7m64.9m65.8m76.4m87.5m98.9m

EBIT

57.3m52.4m56.1m51.4m37.4m31.6m

EBIT margin, %

30%28%29%26%19%15%

Interest expense

897.0k1.6m1.5m

Interest income

44.0k25.0k23.0k67.0k171.0k418.0k

Pre tax profit

57.4m52.1m55.1m50.6m36.4m30.4m

Income tax expense

19.3m17.4m19.5m18.4m14.9m6.5m

Net Income

38.0m34.7m35.5m32.2m21.6m23.8m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

44.8m50.1m47.2m48.0m51.5m48.2m47.2m51.3m50.7m46.8m54.1m50.1m52.3m56.5m51.7m51.5m50.2m48.4m

Cost of goods sold

16.8m18.5m18.0m18.8m19.0m17.9m15.6m17.7m17.8m17.4m20.6m18.9m20.5m21.9m19.8m19.9m20.9m20.2m

Gross profit

28.0m31.6m29.2m29.2m32.5m30.3m31.6m33.6m32.9m29.5m33.5m31.2m31.8m34.6m32.0m31.6m29.3m28.3m

Gross profit Margin, %

63%63%62%61%63%63%67%65%65%63%62%62%61%61%62%61%58%58%

Sales and marketing expense

6.5m6.2m6.2m6.4m7.2m8.1m7.5m8.0m7.9m8.8m8.6m8.5m7.6m6.9m6.7m

R&D expense

2.9m3.2m3.1m3.1m3.4m3.2m3.4m3.1m3.5m3.4m3.9m3.9m4.5m4.2m4.3m4.0m3.8m4.6m

General and administrative expense

7.6m6.3m6.7m7.4m6.9m6.5m8.2m6.9m7.5m8.4m7.4m8.5m8.9m9.1m8.4m8.9m7.4m8.0m

Operating expense total

16.4m15.9m16.1m16.6m16.8m15.9m18.0m18.4m19.2m19.4m19.3m26.9m23.7m26.9m23.2m21.0m19.5m21.8m

EBIT

11.6m15.7m13.1m12.7m15.7m14.4m13.6m15.2m13.7m10.1m14.2m4.3m8.1m7.7m8.7m10.6m9.8m6.5m

EBIT margin, %

26%31%28%26%31%30%29%30%27%22%26%9%15%14%17%20%20%13%

Interest expense

43.0k427.0k423.0k408.0k407.0k395.0k379.0k375.0k363.0k347.0k448.0k

Interest income

4.0k6.0k5.0k6.0k6.0k6.0k17.0k3.0k22.0k22.0k29.0k51.0k72.0k90.0k109.0k149.0k204.0k194.0k

Pre tax profit

11.4m15.6m12.9m12.1m15.5m14.3m13.7m14.8m13.4m9.7m14.2m3.9m7.7m7.2m8.6m10.5m9.2m6.5m

Income tax expense

4.0m5.3m4.0m4.2m5.5m5.2m4.8m5.7m4.6m3.4m4.9m3.7m1.4m1.9m1.8m2.4m2.2m1.4m

Net Income

7.4m10.3m8.8m7.9m10.1m9.1m8.9m9.1m8.8m6.3m9.3m240.0k6.3m5.3m6.8m8.1m7.1m5.1m

Meridian Bioscience Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

44.3m43.0m50.0m47.2m57.1m59.8m

Accounts Receivable

Inventories

34.8m35.5m35.8m45.1m41.5m42.0m

Current Assets

114.1m112.7m122.9m126.8m133.9m139.1m

Goodwill

23.1m23.2m22.3m62.0m54.9m54.6m

Total Assets

176.7m176.9m183.3m251.8m249.8m251.4m

Accounts Payable

5.6m5.0m6.6m7.6m7.7m6.3m

Short-term debt

3.8m4.5m5.3m

Current Liabilities

21.7m13.7m15.3m22.6m22.9m24.2m

Long-term debt

54.6m50.1m44.9m

Non-Current Liabilities

2.2m2.2m62.8m57.3m51.8m

Total Debt

58.4m54.6m50.2m

Total Liabilities

15.9m17.4m85.4m

Additional Paid-in Capital

107.4m111.9m117.2m122.4m125.6m129.2m

Retained Earnings

46.9m48.9m51.1m49.6m46.9m49.6m

Total Equity

155.0m161.0m165.9m166.5m169.6m175.4m

Debt to Equity Ratio

0.4 x0.3 x

Debt to Assets Ratio

0.2 x0.2 x

Financial Leverage

1.1 x1.1 x1.1 x1.5 x1.5 x1.4 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

43.7m38.2m39.3m49.5m42.7m46.0m53.4m48.9m45.8m49.3m54.7m55.3m54.7m56.4m57.9m61.5m66.1m55.2m

Inventories

37.7m38.1m37.6m34.4m33.0m33.6m38.8m41.9m43.4m44.7m42.4m40.9m43.6m43.8m45.2m41.9m40.9m43.3m

Current Assets

111.2m114.0m113.5m114.7m116.5m118.0m123.2m128.2m126.9m126.0m128.8m129.2m136.6m139.5m140.2m139.6m144.7m137.4m

Goodwill

23.4m23.5m23.8m22.6m22.1m22.8m22.1m64.5m63.7m60.7m60.8m54.6m55.0m55.4m54.8m54.4m54.6m90.1m

Total Assets

174.9m178.2m178.8m177.4m178.3m179.3m186.4m258.4m254.9m250.1m251.9m245.1m252.0m254.5m254.0m249.9m254.0m322.4m

Accounts Payable

5.0m7.8m6.4m5.9m6.1m5.5m7.2m7.9m7.4m7.5m6.4m5.9m8.5m7.6m7.4m6.2m7.8m8.4m

Short-term debt

3.0m3.4m4.1m4.5m4.5m4.5m4.5m4.9m5.6m6.0m

Current Liabilities

17.5m17.8m16.9m14.5m15.2m13.3m15.7m21.3m20.2m21.0m19.9m20.0m23.5m25.8m24.5m20.7m24.1m19.8m

Long-term debt

56.8m55.7m53.5m52.4m51.3m49.0m47.9m46.4m43.4m41.9m75.8m

Non-Current Liabilities

2.0m2.0m2.1m2.1m67.2m65.8m63.3m61.2m57.6m55.6m54.4m54.4m50.5m48.2m114.1m

Total Debt

59.8m59.1m57.6m56.9m55.8m53.5m52.4m51.3m49.1m47.9m75.8m

Additional Paid-in Capital

109.5m110.1m110.7m113.5m114.1m114.8m120.2m121.3m121.7m124.2m124.7m125.2m127.4m127.6m128.7m130.9m132.0m132.3m

Retained Earnings

46.4m48.4m49.0m48.4m50.2m50.9m51.5m52.2m52.6m47.5m51.5m46.5m47.9m47.9m49.5m52.3m54.1m59.0m

Total Equity

157.4m160.3m161.8m160.8m161.1m163.9m168.6m169.8m168.9m165.7m170.8m167.5m172.9m174.3m175.1m178.6m181.6m188.6m

Debt to Equity Ratio

0.4 x0.4 x0.3 x0.3 x0.3 x0.3 x0.3 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.5 x1.5 x1.5 x1.5 x1.5 x1.5 x1.5 x1.5 x1.4 x1.4 x1.7 x

Meridian Bioscience Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

38.0m34.7m35.5m32.2m21.6m23.8m

Accounts Receivable

(4.4m)

Inventories

41.5m(1.1m)

Accounts Payable

7.7m4.1m

Cash From Operating Activities

44.4m38.3m42.8m37.2m41.4m34.8m

Purchases of PP&E

(3.2m)(5.3m)(4.6m)(4.0m)

Cash From Investing Activities

(3.3m)(7.0m)(3.6m)(66.7m)(4.5m)(4.2m)

Dividends Paid

(31.4m)(32.8m)(33.4m)(33.6m)(24.3m)(21.2m)

Cash From Financing Activities

(28.6m)(31.8m)(30.7m)27.2m(27.7m)(27.6m)

Interest Paid

879.0k1.6m1.5m

Income Taxes Paid

20.1m20.0m20.2m17.9m12.6m6.6m

Meridian Bioscience Ratios

USDY, 2019

EV/EBIT

69.2 x

EV/CFO

15.8 x

Financial Leverage

1.7 x

Meridian Bioscience Employee Rating

2.050 votes
Culture & Values
2.0
Work/Life Balance
2.4
Senior Management
1.8
Salary & Benefits
2.4
Career Opportunities
2.1
Source